Generic Gleevec 'Fail First' Coverage Policy Would Be Cost Effective – Study
Executive Summary
Payers may have case for steering newly-diagnosed patients away from newer regimens, even though those products have slightly higher efficacy, research by University of Chicago’s Conti suggests.